Annals of Oncology 12:1705-1709, 2001
© 2001 European Society for Medical Oncology
research-article |
Weekly cisplatin and oral etoposide as treatment for relapsed epithelial ovarian cancer
Department of Medical Oncology, Mount Vernon Hospital Northwood, UK
G. J. S. Rustin. M D, Dr. Mount Vernon Hospital, West Herfortshire Hospitals, Department of Medical Oncology, The Clock Tower, Northwood, Middlesex HA6 2RN, UK, E-mail: rustin{at}mtvern.co.uk
Background: Response rates to chemotherapy in relapsed, platinum resistant epithelial ovarian cancer remain poor. We have explored the effectiveness of weekly cisplatin combined with prolonged oral etoposide in this patient group.
Patients and methods: Forty-two women with relapsed, advanced ovarian cancer were treated with cisplatin 60 mg/m2 on days 1, 8, 15, 29, 36 and 43 and oral etoposide 50 mg given from day 1–14 and day 29–43. In those who were responding and tolerating treatment (n = 13) oral etoposide 50 mg was continued for two further cycles (days 1–21 repeated every 28 days). The interval since last platinum containing chemotherapy was > 6 months in 28 patients and ±6 months in 16 patients.
Results: Thirty-six patients were evaluable for response according to CA 125 criteria giving an overall response rate of 44%. The response rate in evaluable patients declined with increasing numbers of previous treatments: 57% with one prior treatment, 42% with two, 40% with three or more. The response rate in patients who had received platinum chemotherapy within six months prior to treatment was 46%. The only significant non-haematological toxicity was nausea and vomiting in 4 patients who experienced greater than grade 2 toxicity. The number of patients experiencing haematological toxicity more than grade 2 was as follows: haemoglobin 3. white blood count 12, platelets 6. Sixteen patients had dose delays and two had dose reductions.
Conclusion We conclude that this short but intensive regimen provides worthwhile response rates, even in those patients who would ordinarily be considered refractory to platinum, and has an acceptable toxicity profile.
CA 125, cisplatin, etoposide, ovarian cancer, relapse
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. J. S. Rustin, R. C. Bast Jr., G. J. Kelloff, J. C. Barrett, S. K. Carter, P. D. Nisen, C. C. Sigman, D. R. Parkinson, and R. W. Ruddon Use of CA-125 in Clinical Trial Evaluation of New Therapeutic Drugs for Ovarian Cancer Clin. Cancer Res., June 1, 2004; 10(11): 3919 - 3926. [Full Text] [PDF]
|
|
|
|
 |
|
 G. J.S. Rustin Use of CA-125 to Assess Response to New Agents in Ovarian Cancer Trials J. Clin. Oncol., May 15, 2003; 21(90100): 187s - 193. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A.E. Guppy and G.J.S. Rustin CA125 Response: Can it Replace the Traditional Response Criteria in Ovarian Cancer? Oncologist, October 1, 2002; 7(5): 437 - 443. [Abstract] [Full Text] [PDF]
|
|